Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study

We carried out a randomized controlled trial using ipragliflozin. We analyzed changes in diastolic function using echocardiography in patients with type 2 diabetes and heart failure with preserved ejection fraction.

[1]  J. Seward,et al.  Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: correlation with autopsy and M-mode echocardiography. , 1996, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[2]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[3]  C. Lang,et al.  A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial , 2020, European heart journal.

[4]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[5]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[6]  Björn Eliasson,et al.  Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes , 2018, The New England journal of medicine.

[7]  H. Krum,et al.  Heart failure and nephropathy: catastrophic and interrelated complications of diabetes. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[8]  M. Packer.  Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events. , 2019, Circulation.

[9]  M. Matsuhisa,et al.  Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study , 2017, Cardiovascular Diabetology.

[10]  Adrian F Hernandez,et al.  Heart failure drug treatment , 2019, The Lancet.

[11]  J. Butler,et al.  Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. , 2017, Journal of the American College of Cardiology.

[12]  Akshay S. Desai,et al.  Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. , 2019, Circulation.

[13]  Danielle M. Enserro,et al.  Temporal Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection Fraction. , 2018, JACC. Heart failure.

[14]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[15]  Juerg Schwitter,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[16]  Deepak L. Bhatt,et al.  Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. , 2019, Circulation.

[17]  Akshay S. Desai,et al.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. , 2019, The New England journal of medicine.

[18]  Vilmundur Gudnason,et al.  Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .

[19]  K. Utsunomiya,et al.  Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes , 2018, Cardiovascular Diabetology.

[20]  Stephen B Wheatcroft,et al.  Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology , 2013, Diabetes & vascular disease research.

[21]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[22]  M. Al-Omran,et al.  Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? , 2016, Diabetes Care.

[23]  K. Hirata,et al.  Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure , 2018, Cardiovascular Diabetology.

[24]  Karl Swedberg,et al.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.

[25]  C. Schneider,et al.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. , 2008, European heart journal.

[26]  E. Braunwald,et al.  Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[27]  J. Oyama,et al.  Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE) , 2020, ESC heart failure.

[28]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[29]  J. Gummert,et al.  Empagliflozin directly improves diastolic function in human heart failure , 2018, European journal of heart failure.

[30]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .